Skip to Content

Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer

Download PQI pdf

Last Updated: May 15, 2026

By: Jennah Bauernfeind, PharmD, BCOP

About this PQI

The purpose of this PQI is to review clinical considerations related to the use of encorafenib combined with cetuximab and FOLFIRI (EC + FOLFIRI) in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI